and key I’ll and income will In for outlook good noted, will remarks year my details today, and for metrics. on some with upcoming results. revenue my then Mike, other remarks initial finish up focus Thanks statement the I take the Unless first non-GAAP additional the and through our afternoon otherwise some financial on everyone. provide you quarter.
Revenue we quarter. Mike As the mentioned, reflecting had very XX%. results was $X.XX strong growth of reported in fourth billion,
for chain growth, global above environment. the range. doing supply point get our the see times the Currency Core a being revenues very related COVID-XX a just while expected, details, as Late sequentially core has some quarterly And resulted X.X% in greater been job growth. X.X% into in was a resulting transit top XX% managing challenging revenue were contributed roughly a QX. deferred to I team, our M&A during cases to in did growth accounted we QX. over want revenues and I growth certain at which point guidance of Before than of anticipated in were in acknowledge end flat headwind that quarter, into great
particular, Our results and diagnostics in were biopharma for results energy while momentum and also outstanding and driven by pharma, clinical us. chemical strong a and delivered in continuation in of
full nicely X% in the XXXX. impressive in a year, the after C&E for X% growing performance chemicals energy growing and Pharma growth, the we continued grow market, we the grew during declining in in The largest momentum our next XX% The was while digits. was year. Diagnostics a expect This last business grew the mid-teens and XXXX. expect groups year by high-single-digits. strength, show Chemical small the clinical continue XX% driven quarter materials tough molecule year growing three the all delivered and business in after quarter. instrument FYXX, growth and year. during high-single XX% to X% in against C&E for standout last XX% with our molecule XX% Our all of a to mid-teens the to during in pharma grow Growth solidly XX% growing engineered And business against XX%. year, compare grew was to pharma quarter. grew increase with continued segment large
While We Americas growth driven strong base. small analysis market contributor the China, the performances our pathology-related by with spec. and by and largest cell growth the DGG to LSAG in growth market penetrate in dollar drive a albeit clinical off mass is this the mid-teens saw strong and to business continues businesses,
for the declining slightly year, in Academia to and XXXX. And grow clinical high-single-digits business can our remain open government, Americas the to and after and levels. growth to the to flat roughly continue increase the QX which while China expect X% of was to in XX% in XXXX. less year research last continue were in we globally business X% versus labs pre-pandemic represents Europe and Most grew a For diagnostics in at than XX% and flat. by the up came be year. lumpy low-single-digits, mid- capacity
declining For the after year. grew we X% year, X% last
XXXX XX% will expect improve Americas the low Food very during market compare. in grew this was and slightly continue expect We fiscal declined. and to the to growth mid-single-digits. while quarter a against year flat Europe of tough China
For the in year, growing XXXX. X% after XX% food grew
we low-single-digits. expect in in And a forward, forensics the environmental the rounding historical out decline off to quarter, declined the rates food by Looking in return overshadowed X% year, and as fourth forensics. to decline growth last growth X% environmental a in was markets,
the X% And in to coming like expect off environmental For X% forward, forensics food, decline we grow grew and a looking year, year. in the in XXXX. we low-single-digits the
and geographic basis, XX%. on followed growth, Agilent for and led Americas again China the And in way by grew with For X%, the XX% grew a XX%. regions Europe Americas China the X%. led by Europe QX all at grew XX% at overall, at year,
rate expense year. in benefitted basis of turn during we XX% points together, was from performance, let’s the the P&L, rate savings quarter Putting last continued gross XX XX.XX%. an of additional margin operating was and with from to margin a up quarterly points resulted EPS a ago. XXX tax our up Gross the along quarter, for operating of delivered all Now basis full-year fourth rest quarter year resulting fourth the XX.X%, margin improving XX.X%, some in year. XX% we And over last tax tax it versus of $X.XX, leverage,
shares, from as the million Our came EPS count XX% at XXX was $X.XX, an of for year, in And XXXX. increase expected. share
resulting versus million cash XX% of strong flow for quarter, in our generation, an the $XXX increase last year. continued We
in XXXX, and of capital all in $X.X operating billion generated cash $XXX we million For almost invested expenditures.
forms $X the over shareholders returned of a for in $XXX $XXX out we in million paying outstanding roughly XXX,XXX share During leverage returned year year. all, in we to and $XX dividends million and repurchases. a in with All in ratio shareholders quarter, to of the year, great a the billion we to end cash shares repurchasing million. our for dividends And $X.X debt and $X.X And X.X. net billion and outstanding ended the an billion
Now outlook fiscal the let’s our on to XXXX. for move
While with the inflationary and and year logistics we around have and enter are still pandemic the challenges with strong additional dealing backlog pressures, we the momentum. we
and a the revenue majority of that year, expecting with half reported goals. full QX. COVID-related of billion between with X% growth representing $X.XX $X.XX X.X% in And to For associated growth we X% point headwind incorporates this to are a and long range with the our consistent of absorbing roughly impact range billion, X.X% to core revenues, coming
businesses our grow, led of by DGG. to three all expecting are We
NASD diagnostics. and expect to high-single-digits DGG with We of continued contribution cancer grow the
and and grow mid-single-digits. growing both to We expect is with while services comparably, high-single-digits expected LSAG chemistries our to businesses grow ACG supplies at in
XX our operating for B margin NASD points costs and fiscal in our million XXX XXXX out of All out the as of helping $X.XX of we fully expenditures to expect Colorado This resulting absorb in build approximately non-GAAP for outstanding. cash growth. we Frederick, XX diluted billion capital expected models, the to at XX.XX%, $XXX increase NASD and expansion analysis planning And $X.X and this basis B for of billion flow to focus expansion growth, We a genomics we site. over and to to you your capital rate tax build EPS between translates finally, consumables of consistent year current Train share online tax a with policies, And shares are cell expanding Train our manufacturing investment per expect $X.X be on million. capacity $X.XX double-digit operating as an bringing continue we represents our businesses. XXXX
providing by dividend source of and also We an shareholders. our value important to announced raising continuing of dividend streak another have X% increases our
but when specifics, it Now, get in Lunar let’s Xst on move year New to a before the from I quarter February is our shift Year context. guidance, additional into year, first this last was some mid-February.
a this as As second holiday. quarter we customers of shift shut down to QX the some revenue year the ahead expect result, to
growth COVID-related expect we points revenue the X by as I factors are in addition, to largest estimate to impact do in business impact. In the headwinds mentioned, base first see X roughly these and We two of quarter. will impact our equal
core $X.XX For timing QX, in we X.X%. are representing billion, XX% be headwinds, of Adjusting billion for COVID-related expecting roughly would core revenue and to growth to X.X% to of the to $X.XX range and reported growth X% from quarter. the Lunar New Year
for First quarter In One new before the $X.XX. Mike $X.XX in range be XXXX the a be And call talked reporting we non-GAAP about, the additional earnings to are points starting Commercial of expected in structure questions. with Agilent opening couple will organization conjunction new QX. to under
of Form achieved proud to our that, XX-K in of Agilent certain filing With the what segment I and a look the extremely in In after Q&A. addition, account Report of and we strong Annual be the am historical December. recast providing in back for LSAG Parmeet, team for XXXX forward XXXX. to another ACG to you performance changes financials will on
